Biblio
Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transplant. 2024.
Hematopoietic cell transplantation (HCT) in MDS patients of older age. Leuk Lymphoma. 2024:1-15.
. Hematopoietic Cell Transplantation in the Management of Myelodysplastic Syndrome: An Evidence-Based Review from the ASTCT Committee on Practice Guidelines. Transplant Cell Ther. 2022.
Hematopoietic stem cell boost for persistent neutropenia after CAR-T cell therapy: a GLA/DRST study. Blood Adv. 2022.
HLA mismatched donors in patients with myelodysplastic syndrome: an EBMT registry analysis. Biol Blood Marrow Transplant. 2018.
. Impact of disease burden on clinical outcomes of AML patients receiving allogeneic hematopoietic cell transplantation: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2023.
Impact of PPM1D Mutations in Patients with Myelodysplastic Syndrome and Deletion of Chromosome 5q. Am J Hematol. 2021.
Impact of pre-transplantation depression and anxiety on the outcome of allogeneic hematopoietic stem cell transplantation: a study from the Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2023.
Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood. 2023.
Incidence and Outcome of Late Relapse after Allogeneic Stem Cell Transplantation for Myelofibrosis. Biol Blood Marrow Transplant. 2020.
. Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group. Lancet Haematol. 2023.
Induction, bridging or straight ahead the ongoing dilemma of allografting in advanced MDS. Biol Blood Marrow Transplant. 2019.
. KIR2DS4 and its variant KIR1D in KIR-AA genotype donors showed differential survival impact in patients with lymphoid disease after HLA-matched unrelated hematopoietic stem cell transplantation. Transplant Cell Ther. 2023.
Long-term survival benefit after allogeneic hematopoietic cell transplantation in chronic myelomonocytic leukemia. Biol Blood Marrow Transplant. 2020.
Methodological challenges in the development of endpoints for myelofibrosis clinical trials. Lancet Haematol. 2024.
Organ complications after CD19 CAR T-cell therapy for large B cell lymphoma: a retrospective study from the EBMT transplant complications and lymphoma working party. Front Immunol. 2023;14:1252811.
Outcome after transplantation according to reduced intensity conditioning regimen in patients transplanted for myelofibrosis. Biol Blood Marrow Transplant. 2016.
OUTCOME OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS OVER 69 YEARS OF AGE WITH ACUTE MYELOID LEUKEMIA: ON BEHALF OF THE ACUTE LEUKEMIA WORKING PARTY OF THE EBMT. Biol Blood Marrow Transplant. 2019.
Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M. Leukemia. 2023.
Outcomes of Cord Blood Transplantation Using Reduced Intensity Conditioning for Chronic Lymphocytic Leukemia: a Study on Behalf of Eurocord and Cord Blood Committee of Celular Therapy and Immunobiology Working Party(CTIWP), Chronic Malignancies Working Pa. Biol Blood Marrow Transplant. 2015.
.